Search Results
Results found for "Evaxion Biotech"
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
that closed door lit the fuse for a career that would reimagine GPCR therapeutics — and lead to two biotech What followed was a scientific journey that now spans two biotech startups, and a bold reimagining of It was investor rejections, endless slide decks, and the steep learning curve of biotech business. Launching Blue was Ajay’s first hands-on experience with biotech entrepreneurship. Lessons From the Front Lines of Biotech Ajay’s experience in both early-stage biotech and academic science
- G.CLIPS biotech is 2 years old this month!
July 2022 "G.CLIPS biotech is 2 years old today🎂. Looking forward for more 🎊 #team #grateful #biotech #work #birthdaycelebration" Read more at the source
- Carola Weiss joins InterAx Biotech AG as VP Business Development
February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner, Yamina's Corner, biotech development, pharmaceutical, scientific career Hashtags: #DrGPCR #GPCR #DrugDiscovery #Pharmacology #Biotech
- InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech #ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery
- Exscientia welcomes Richard J. Law, as their new Chief Business Officer
the architect behind nearly all of Exscientia's partnerships and collaborations across pharma and #biotech
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
This simple truth applies profoundly to the "go fast" culture in biotech. I work with biotechs, VCs, and CROs to implement the framework that ensures every step forward is strategic
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
#biotech #lifesciences #appointment #GPCR #Oncology" Read more at the source #DrGPCR #GPCR #IndustryNews
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who
- AELIS PHARMA launches their IPO for €25 million
#IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the
- SYnAbs is now officially accredited as a Research Tax Credit by the French Ministry of Higher...
immunology #antibodies #medicine #cancer #innovation #gpcr #synabs #monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals #oncology #healthcare
- GPCR Happy Hour – Boston, Sept 2025
When the biotech world gathers in Boston, this is where the real conversations begin. Every September, Boston welcomes the global biotech and drug discovery community. Why It Matters Connect with peers across biotech, CROs, and investment who are driving discovery forward Meet both the global biotech community and Boston’s local innovators in one room Be part of Dr. Our mission is simple: bridge science and industry by connecting researchers, biotech, CROs, and pharma
- From GPCR Data Chaos to Decisive Action
Hidden Cost of Good Science Without Systems I’ve seen this pattern again and again—across academia, biotech This is embedded consulting for biotech and VC teams who need to move fast —without compromising scientific Who I Work With ✅ Biotech Teams – Especially those lacking in-house GPCR leads or overwhelmed by CRO assets in their portfolio. ✅ Contract Research Organizations (CROs) – Wanting to better align with biotech
- Inverse Agonists, Lymphatic Fixes & β-arrestin Tricks
GPCR tools and key moves in the biotech world. Dr. Explore this week’s research, tools, and biotech insights in one place.
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Corner delivers this week: high-impact insight into GPCR allostery, crafted for pharmacologists and biotech nuance into better decision-making. 🔍 This Week in Premium: Sneak Peek Industry insights: Strategic biotech This is where funders, peers, and biotech scouts are watching. GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who
- How Advanced GPCR Kinetics Sharpen Decision Making (and Save You Time)
Breakthroughs this week: Septerna begins first-in-human trial of SEP-631 for CSU; Maxion’s KnotBody® GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- Mapping Motion: Intermediate States, Deorphanization & Discovery
Meanwhile, the industry is moving fast with AI-powered platforms, bold leadership moves, and strategic biotech Explore this week’s research, tools, and biotech insights in one place.
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
Discovery at Discovery on Target 2025 — The Track You Can’t Miss If you work in drug discovery or biotech Over the years, we’ve built a global network of researchers, biotech leaders, and pharma innovators who together. 🚨 Mark your calendar for the GPCR Happy Hour Join us at GPCR Happy Hour , where scientists, biotech
- How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision
Ajay Yekkirala shares the journey from academic pharmacologist to biotech entrepreneur—bridging curiosity When the global biotech crowd lands in Boston for Discovery on Target. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
Tools The Story Behind Celtarys – From Chemistry to Company How does a medicinal chemist become a biotech Explore this week’s research, tools, and biotech insights in one place.
- Understanding Enzyme Inhibition In GPCR Discovery Programs
Kenakin Trusted insights across biotech, pharma, and academia 💎 $2,999/year — one conference cost = embracing serendipity, Eric shares the mindset (and messy origin stories) that shaped tools now used across biotech GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- Dr. GPCR Updates
Dive into this week’s research, tools, and biotech updates all in one place.
- From Lab Bench to Boardroom: The Unexpected Path of a Medicinal Chemist
Watch Episode 168 What does it take for a scientist to become a startup leader in biotech? For Dr.
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
work at Alkermes didn’t just improve drug screening outcomes, it redefined what great leadership in biotech
- Inside Out: Mapping GPCRs from Membrane Codes to Market Moves
Explore this week’s research, tools, and biotech insights in one place.
- Irreversible Drugs, Real Control: Design for Durable Target Engagement
Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers Curious about GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
In this podcast, he lays out the mindset that helped shape products used across biotech and academia—and teaming, testing, and failing smarter. 🚀 Why This Matters: Whether you’re launching a tool, starting a biotech
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
His hybrid path is a model of possibility for professionals in the biotech industry who still dream of
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need tools, translational strategy, classified updates, and curated jobs—trusted by scientists, teams, and biotech